Medical articles
A New Cyber Concern: Hack Attacks on Medical Devices
Personal Grooming Products May Be Harming Great Lakes Marine Life
Location May Stymie Wind and Solar Power Benefits
Lead Costs Developing Economies Nearly $1 Trillion Annually
Sweet ‘n Sour: A Common Sugar May Help Pathogens Conquer the Human Gut
NIH Will Curb Research on Chimps
Is Age the Main Factor in Nelson Mandela's Lung Infection?
Gut Microbes Spur Liver Cancer in Obese Mice
A Father's Genetic Quest Pays Off
EPA Defends Chemical Testing of Low-Dose Hormone Effects
Deadly piglet virus spreads to nearly 200 U.S. farm sites
E-cigarettes may help smokers quit, study suggests
Breast-fed children more likely to climb the social ladder
Weight loss doesn't reduce heart problems for some
Talking to teens about weight loss tied to unhealthy dieting, laxative use
5 ways to grill food safely
Menopause hormone use not linked with cognitive problems
Genes known to cause birth defects may also lead to mental illness
7 African countries cut child HIV infections by half
Woman drinks only soda for 16 years, suffers heart problems
Is iron deficiency causing psychiatric disorders in kids?
Common meds containing caffeine may be linked to stroke
Could Obama’s climate plan help decrease asthma rates?
Is raw milk safe to drink?
  US FDA approves new Baxter drug for hemophilia B
Patients with a form of the chronic blood disorder hemophilia will soon have a new therapy that not only treats episodes of excessive bleeding, but helps to prevent them.

The Food and Drug Administration on Thursday granted U.S. marketing approval for Rixubis, a genetically engineered protein made by Baxter International Inc that represents the first new treatment for the genetic disorder in more than 15 years.

Hemophilia B is the second most common type of hemophilia, which affects 3,300 people in the United States and some 25,000 worldwide, according to the National Hemophilia Foundation.

It arises when people make insufficient blood clotting factor that naturally controls bleeding.

Rixubis, which is administered twice weekly, aims to control and prevent bleeding and better manage hemophilia B patients in the hospital for surgery. It can also be used routinely to prevent or reduce bleeding.

The drug was approved based on a late-stage trial of 73 male patients. It found that three-quarters of those who took the drug on a routine basis had a 75 percent lower annual bleeding rate compared with those who were treated only when bleeding episodes occurred. The most common side effects were distorted taste, extreme pain, atypical blood test results and anaphylaxis, a life-threatening allergic reaction.

Baxter studied the drug in patients aged 12 to 65, but the company now plans to study the drug in a younger populations.

Hemophilia B is one of two forms of the disease and occurs in about one in 25,000 male births. The most common form is called hemophilia A and occurs in more than 400,000 people worldwide, according to the National Hemophilia Foundation.

Omega-3 in fish may reduce breast cancer risk
Wait-and-see approach for prostate cancer questioned for black men
Surgery helps baby with severely swollen head
Face transplant patient celebrates life in public
UK may approve creating babies with DNA from 3 people
More frozen berries recalled over hepatitis A concerns
Woman's 'foot orgasm' is first known case
Good Samaritan who saved drowning girl dies from injuries weeks after rescue
Regulators pave way for biosimilar drug breakthrough
Pennsylvania hospitals' ban on hiring smokers prompts debate
New labels tied to fewer child poisonings by over-the-counter meds
'True Blood' star Joe Manganiello is even tougher than you think
Is your baby overweight? What you need to know
‘Supernanny’ takes on allergies
New clot preventer works as well as warfarin with less bleeding
FDA approves first nonhormonal drug for hot flashe
Differences between the sexes stretches to fitness formulas
Premature ejaculation: Why men should discuss it with their doctors
Tobacco taxes, smoking bans set to save millions of lives, study says
WHO: Treat people with HIV early to stop disease's spread
Fears of MERS virus at Muslim hajj pilgrimage
Parents beware: Kids' wire hampers pose eye dangers
Heat waves: What you need to know
Rare condition causes 16-year-old girl to look like a middle-aged woman
FDA rejects Merck insomnia drug, seeks lower-dose
Watching an avatar may help some lose weight
Painful problem: Why more kids are facing chronic pain
Infertility May Be Linked to Taste Genes
Lawsuit blames Monster energy drinks for California teen's death
Mexico restricts US live hog imports due to piglet virus
Lure, variety of designer drugs is alarming, U.N. agency says
Heart disease deaths show dramatic decline in Europe
6 simple tips for better sleep
Aspirin cuts colon cancer risk, study suggests
A guide to summertime emergencies
Rise in high-end treatment for low-risk prostate cancer
A tongue patch for weight loss?
New 'digital dementia' plaguing young tech users
The scariest infectious diseases right now
Dr. Manny: Marriage equality has health benefits for all
Breakthrough ‘reverse’ vaccine may help combat Type 1 diabetes
More C-sections are now done closer to due date
Melanoma deaths more likely in young men than women
New rules aim to rid schools of junk food
Why carbs may cause food cravings
New way to treat Parkinson's disease
Are Chinese herbs safe to use?
Vietnam War veterans with PTSD have higher risk of heart disease
Heavy drinkers have more post-surgery problems
History of marriage: 13 surprising facts
Drug combo decreases likelihood of stroke for those already at risk
US FDA approves new Baxter drug for hemophilia B